Novo Nordisk AS (OCSE:NOVO B)
kr 757.3 9.7 (1.3%) Market Cap: 3.36 Til Enterprise Value: 3.35 Til PE Ratio: 35.72 PB Ratio: 27.97 GF Score: 97/100

Q3 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) Transcript

Nov 03, 2023 / 01:15PM GMT
Release Date Price: kr683.9 (-3.61%)
Richard Vosser
JPMorgan Chase & Co, Research Division - Senior Analyst

Welcome to everyone in the room, welcome to everyone on the line to view the lunch meeting at the Novo Nordisk 9 Months Roadshow. I'm Richard Vosser, European pharma analyst at JPMorgan. It's my great pleasure to host Novo today, and I'll just get out of the way and hand over to Kasim for a few introductory remarks, and then we'll go to Q&A. Kasim?

Kasim Kutay;S;Non;Independent Director
Novo Nordisk A

/--

Thank you, Richard Vosser. And thank you to JPMorgan for hosting Novo Nordisk and our Q3 roadshow presentation. As you can imagine, we're in a very good place. It's amazing results at Novo Nordisk these days, growing more than 30% top and bottom line organically. And very good progress on pipeline, SELECT readout, flow interim. So a pleasure to be here this quarter. I'm here with Camilla Sylvest, our Head of Corporate Affairs and Commercial Strategy. And Martin Lange, Head of Development. So this is really the dream team being here.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot